References
Satteson E, Tannan SC. De Quervain Tenosynovitis. 2018 Nov 18.StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK442005/ PubMed PMID: 28723034.
2. Oh JK, Messing S, Hyrien O, Hammert WC. Effectiveness of Corticosteroid
Injections for Treatment of de Quervain’s Tenosynovitis. Hand (N Y). 2017;12: 357-361.
3. Wagner ER, Gottschalk MB. Tendinopathies of the Forearm, Wrist, and Hand.Clin Plast Surg. 2019 ; 46: 317-327.
4. Ippolito JA, Hauser S, Patel J, Vosbikian M, Ahmed I. Nonsurgical Treatment of De Quervain Tenosynovitis: A Prospective Randomized Trial. Hand (N Y). 2018; 30:1558944718791187.
5. Pensak MJ, Bayron J, Wolf JM. Current treatment of de Quervain tendinopathy. J Hand Surg Am. 2013; 38: 2247-2249.
6. Hadianfard M, Ashraf A, Fakheri M, Nasiri A. Efficacy of acupuncture versus local methylprednisolone acetate injection in De Quervain’s tenosynovitis: a randomized controlled trial. J Acupunct Meridian Stud. 2014 ;7:115-121.
7. da Silva JB, Batigália F. Acupuncture in De Quervain’s disease: a treatment proposal. Acupunct Med. 2014;32:70-72.
8. Rabago D, Nourani B. Prolotherapy for Osteoarthritis and Tendinopathy: a Descriptive Review. Curr Rheumatol Rep. 2017;19:34.
9. Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:139-159.
10 . Fischer, L., Neuraltherapie. Neurophysiologie, Injektionstechnik und Therapievorschläge. 4. Aufl. Haug, Stuttgart, 2014.
11. Nazlikul H. Nöralterapi Ders Kitabı. Nobel Kitapevi, Istanbul, 2010.
12 . Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health.1990; 13: 227-236.
13. Duruöz MT, Poiraudeau S, Fermanian J, Menkes CJ, Amor B, Dougadous M et al. Development and validation of a rheumatoid hand functional disability scale that assesses functional 360 handicap. J Rheumatol.1996; 23: 1167-1172.
14 . Puente de la Vega Costa K, Gómez Perez MA, Roqueta C, Fischer L. Effects on hemodynamic variables and echocardiographic parameters after a stellate ganglion block in 15 healthy volunteers.Auton Neurosci. 2016;197: 46-55.
15. Lane LB, Boretz RS, Stuchin SA. Treatment of de Quervain’s disease: role of conservative management. J Hand Surg Br . 2001;26:258-260.
16. Stepan JG, London DA, Boyer MI, Calfee RP. Blood glucose levels in diabetic patients following corticosteroid injections into the hand and wrist. J Hand Surg Am. 2014;39:706-712.
17. Shin YH, Choi SW, Kim JK. Prospective randomized comparison of ultrasonography-guided and blind corticosteroid injection for de Quervain’s disease. Orthop Traumatol Surg Res. 2020;106:301-306.
18 . Omoke NI, Nnadozie UU. Clinical Outcome of Nonoperative Treatment of de Quervain’s Disease with Local Corticosteroid Injection in Nigerian Setting. Niger J Surg. 2019 ;25:146-152.
19. Baldry PE. Acupuncture, trigger points and musculoskeletal pain. 3rd edn. Oxford, UK: Elsevier Ltd, 2005.
20. Kuo YL, Hsu CC, Kuo LC, Wu PT, Shao CJ, Wu KC, et al. Inflammation is present in De Quervain’s disease – Correlationstudy between biochemical and histopathological evaluation.Ann Plast Surg. 2015; 74: 146-151.
21. Cassuto D, Sinclair R, Bonderovic M. Anti-inflammatory properties of local anesthetics and their present and potential clinical implications. Acta Anaesthesiol Scand. 2006; 50: 265–282.
22. Egli S, Pfister M, Ludin SM, Puente de la Vega K, Busato A, Fischer L. Long-term results of therapeutic local anesthesia (neural therapy) in 280 referred refractory chronic pain patients. BMC Complement Altern Med. 2015; 15: 200-211.
23. Simons DG, Travell JG, Simons LS. Myofascial Pain and Dysfunction: The Trigger Point Manual. Vol. 1. Lippincott William & Wilkins, Philadelphia, 1999.
24. Fischer L. Myofasciale Trigger punkte und Neuraltherapie nach Huneke. EHK.1998; 3: 117–121.
25. Nazlıkul H, Ural FG, Öztürk GT, Öztürk ADT. Evaluation of neural therapy effect in patients with piriformis syndrome.J Back MusculoskeletRehabil.2018; 31: 1105-1110.
26. Fischer L. Pathophysiologie des Schmerzes und Neuraltherapie. Praxis.2003; 92: 2051–2059.
27. Weinschenk S. Neural therapy—A review of the therapeutic use of local anesthetics.Acupuncture and Related Therapies.2012; 1: 5–9.
28 . Balevi Batur E, Atan T. Neural therapy for fibromyalgia: Myth or improving quality of life? Int J Clin Pract. 2021;75:e13719.
29. Tamam Y, Özdemir HH, Gedik A, Tamam C, Nazlıkul H. Efficacy of peripheral lidocaine application (neural therapy) in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Neurourol Urodyn. 2017; 36: 1832-1838.
30. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. Anesthesiology.2018; 129: 343-366.
31. Salvaggio I, Adducci E, Dell’Aquila L, Rinaldi S, Marini M, Zappia L, Mascaro A. Facial pain: a possible therapy with stellate ganglion block. Pain Med. 2008; 9: 958-962.
Table 1. The socio-demographic and clinical characteristics of the participants